BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)5.24
  • Today's Change-0.24 / -4.38%
  • Shares traded1.32m
  • 1 Year change57.83%
  • Beta3.5282
Data delayed at least 15 minutes, as of May 22 2017 21:00 BST.
More ▼

Events & Activity

  • BCRX:NSQ price moved over -2.70% to 5.41
  • BCRX:NSQ price falls below 200-day moving average to 5.41 at 10:30 BST
  • BCRX:NSQ price falls below 200-day moving average to 5.55 at 15:09 BST
  • BCRX:NSQ price rises above 200-day moving average to 5.64 at 10:30 BST
  • BCRX:NSQ trading volume exceeds daily average by +15.40%

Key statistics

On Monday, BioCryst Pharmaceuticals Inc (BCRX:NSQ) closed at 5.24, 101.54% above the 52 week low of 2.60 set on Jun 24, 2016.
52-week range
2.60Jun 24 20169.25Mar 21 2017
Markit short selling activity
Previous close5.24
Average volume1.56m
Shares outstanding80.42m
Free float79.28m
P/E (TTM)--
Market cap440.71m USD
EPS (TTM)-0.6275 USD
Data delayed at least 15 minutes, as of May 22 2017 21:00 BST.
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.